Memorial Sloan Kettering – Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects

The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.

Read more

Study Reveals New Way to Treat Stroke Using an Already FDA-Approved Drug

Granulocyte colony-stimulating factor (GCSF) is currently used to treat neutropenia due to chemotherapy and has been successfully used for patients who require bone marrow transplants. The study is the first to report on the neuroprotective effect of GCSF in vivo and showed that it improved neurological deficits that occur in the first few days following cerebral ischemia. GCSF improved long-term behavioral outcomes while also stimulating a neural progenitor recovery response in a mouse model.

Read more

Mutations in donors’ stem cells may cause problems for cancer patients

A new study from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells — though not causing health problems in the donors — may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients. Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.

Read more

New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients

The National Comprehensive Cancer Network (NCCN) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation, (aka stem cell transplant or bone marrow transplant), with step-by-step information on best practices for this blood cancer treatment

Read more